Not available
Quote | Verona Pharma plc (NASDAQ:VRNA)
Last: | $14.85 |
---|---|
Change Percent: | 0.34% |
Open: | $14.7 |
Close: | $14.85 |
High: | $15.11 |
Low: | $14.7 |
Volume: | 762,316 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
News | Verona Pharma plc (NASDAQ:VRNA)
2024-05-09 13:54:49 ET More on Verona Pharma Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation Verona Pharma GAAP EPS of -$0.04 ...
2024-05-09 12:31:02 ET Verona Pharma plc (VRNA) Q1 2024 Results Conference Call May 09, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer Christopher Martin - Chief Commercial Offi...
Message Board Posts | Verona Pharma plc (NASDAQ:VRNA)
Subject | By | Source | When |
---|---|---|---|
https://seekingalpha.com/article/4594258-verona-pharma-ensifentrine-vs-dupixent- | Amatuer17 | investorshub | 04/16/2023 11:57:08 PM |
Great news today AH - this little pharm | 4Godnwv | investorshub | 02/02/2023 12:25:44 AM |
25.77 | TheFinalCD | investorshub | 12/30/2022 8:11:15 PM |
COPD is a crowded place - not sure | Amatuer17 | investorshub | 12/30/2022 6:23:41 PM |
Very few sure bets on Nasdaq. | Laster | investorshub | 12/30/2022 5:18:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Verona Pharma plc Company Name:
VRNA Stock Symbol:
NASDAQ Market:
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities Cash runway extended beyo...
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 09, 2024...
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine’s clinical activities Cash runway extended beyond 2026 LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”),...